Pipeline Licensing Service

Porton Advanced has been offering comprehensive CRO and CDMO support to over 100 clients across the globe for their gene and cell therapy endeavors. These biotech startups harbor strong convictions regarding the substantial potential of their drug products and technologies within the dynamic pharmaceutical landscape. Some are even open to licensing out these assets to international innovators. Our ability to engage with these companies at their early stages fills us with excitement as we endeavor to facilitate connections between these innovators and showcase our clients' assets across various markets.

Available Pipelines

Pipeline Therapies Target Indication Stage
PAS-001 CAR-T NKG2DL Glioblastoma, Colorectal Cancer, Hepatocellular Carcinoma

IND approval in China

PAS-002 CAR-T NKG2DL, CLDN18.2 Pancreatic Cancer, Gastric Cancer

Investigator-initiated clinical trials* (Pre-IND) in China

PAS-003 CAR-T NKG2DL, CD33 Acute Myeloid Leukemia

Preclinical research in China

PAS-009 CAR-T Mesothelin Recurrent Ovarian Carcinoma

IND approval in China

PAS-010 CAR-T Mesothelin Advanced Ovarian Carcinoma

IND approval in China

PAS-011 CAR-T CD19 (R/R) B-ALL

NDA approved (NMPA)

*Investigator-initiated clinical trials (IIT) in China are conducted before IND application and support drug development.

Contact Us For More Details

We have basic information for all the pipelines listed above, including modalities, targets, indications, safety and efficacy data, and clinical data. Should you be interested, please get in touch with us and ask for more details.

Contact Us
Shopping Basket
Scroll to Top